Vertex to buy diabetes biotech firm for $950m

04-09-2019

Sarah Morgan

Vertex to buy diabetes biotech firm for $950m

Pavel Kapysh / Shutterstock.com

US-based Vertex Pharmaceuticals has announced it will pay $950 million to acquire Semma Therapeutics, a biotechnology company focused on researching a cure for Type 1 diabetes.


Vertex Pharmaceuticals, Semma Therapeutics, biotech, diabetes, mergers and acquisitions, M&A, cell delivery, insulin secretion

LSIPR